Atrion (NASDAQ:ATRI) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Tuesday.
Atrion (NASDAQ ATRI) traded down $6.90 on Tuesday, hitting $597.00. 2,300 shares of the company were exchanged, compared to its average volume of 4,186. Atrion has a 12 month low of $454.10 and a 12 month high of $694.00. The firm has a market cap of $1,090.00, a price-to-earnings ratio of 33.07 and a beta of 0.85.
Atrion (NASDAQ:ATRI) last posted its earnings results on Wednesday, November 8th. The medical instruments supplier reported $4.29 earnings per share for the quarter. Atrion had a net margin of 22.98% and a return on equity of 18.34%. The company had revenue of $37.90 million for the quarter.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Neuberger Berman Group LLC raised its holdings in shares of Atrion by 4.0% in the 3rd quarter. Neuberger Berman Group LLC now owns 86,185 shares of the medical instruments supplier’s stock worth $57,916,000 after acquiring an additional 3,291 shares during the last quarter. Vanguard Group Inc. grew its position in Atrion by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 79,246 shares of the medical instruments supplier’s stock worth $50,979,000 after purchasing an additional 1,676 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Atrion by 1.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 64,290 shares of the medical instruments supplier’s stock worth $43,203,000 after purchasing an additional 1,022 shares in the last quarter. Renaissance Technologies LLC grew its position in Atrion by 46.3% in the 2nd quarter. Renaissance Technologies LLC now owns 58,834 shares of the medical instruments supplier’s stock worth $37,848,000 after purchasing an additional 18,633 shares in the last quarter. Finally, State Street Corp grew its position in Atrion by 3.0% in the 2nd quarter. State Street Corp now owns 31,790 shares of the medical instruments supplier’s stock worth $20,446,000 after purchasing an additional 919 shares in the last quarter. Institutional investors own 59.01% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “BidaskClub Downgrades Atrion (ATRI) to Strong Sell” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/11/bidaskclub-downgrades-atrion-atri-to-strong-sell.html.
Atrion Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.